New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lilly Endowment Inc, a significant shareholder of Eli Lilly & Co, has made notable transactions involving the sale of company stock. The endowment sold 15,632 shares, amounting to $17,340,531, followed by another sale of 147,061 shares valued at $161,081,869.
Recent Updates on LLY stock
Eli Lilly & Co. has announced updates on several ongoing clinical studies, which could significantly impact its stock performance. The company is conducting a Phase 2 study on brenipatide for smoking cessation, a Phase 3 study on baricitinib for preserving beta-cell function in type 1 diabetes, and another Phase 3 study to delay diabetes onset in at-risk individuals. Additionally, a Phase 4 study is evaluating the long-term safety of pirtobrutinib in chronic lymphocytic leukemia patients, and a Phase 3 trial is assessing the efficacy of Vepugratinib in combination with other drugs for advanced urothelial carcinoma. These studies highlight Eli Lilly’s efforts to expand its portfolio in smoking cessation, diabetes management, and oncology. Successful outcomes could enhance investor sentiment and position the company favorably against competitors, potentially leading to positive stock performance.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The company’s robust revenue growth and strategic advancements outweigh the high valuation and technical indicators suggesting an overbought condition. However, potential risks from high leverage and declining cash flow metrics should be monitored.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: 44.85%
Average Trading Volume: 3,795,310
Technical Sentiment Signal: Buy
Current Market Cap: $1049.3B